Axsome Therapeutics Inc. (NASDAQ:AXSM) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.
Brokers have set a twelve-month consensus price target of $23.33 for the company, according to Zacks. Zacks has also given Axsome Therapeutics an industry rank of 111 out of 265 based on the ratings given to its competitors.
A number of equities analysts have commented on AXSM shares. Zacks Investment Research lowered shares of Axsome Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. Brean Capital restated a “buy” rating on shares of Axsome Therapeutics in a research note on Wednesday, August 10th. Finally, Cantor Fitzgerald set a $13.00 target price on shares of Axsome Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 10th.
Shares of Axsome Therapeutics (NASDAQ:AXSM) opened at 7.29 on Wednesday. The firm’s market cap is $139.60 million. Axsome Therapeutics has a 12 month low of $5.37 and a 12 month high of $15.74. The company has a 50-day moving average of $7.65 and a 200-day moving average of $8.37.
Large investors have recently modified their holdings of the stock. Teachers Advisors Inc. bought a new stake in shares of Axsome Therapeutics during the second quarter worth about $128,000. Schwab Charles Investment Management Inc. acquired a new stake in Axsome Therapeutics during the second quarter valued at $134,000. Bank of New York Mellon Corp acquired a new stake in Axsome Therapeutics during the second quarter valued at $161,000. California State Teachers Retirement System acquired a new stake in Axsome Therapeutics during the second quarter valued at $176,000. Finally, BlackRock Investment Management LLC raised its stake in Axsome Therapeutics by 3,828.0% in the second quarter. BlackRock Investment Management LLC now owns 38,062 shares of the company’s stock valued at $287,000 after buying an additional 37,093 shares during the period. Institutional investors and hedge funds own 30.30% of the company’s stock.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.